JP2012513411A5 - - Google Patents

Download PDF

Info

Publication number
JP2012513411A5
JP2012513411A5 JP2011542581A JP2011542581A JP2012513411A5 JP 2012513411 A5 JP2012513411 A5 JP 2012513411A5 JP 2011542581 A JP2011542581 A JP 2011542581A JP 2011542581 A JP2011542581 A JP 2011542581A JP 2012513411 A5 JP2012513411 A5 JP 2012513411A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
activity
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011542581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012513411A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/069297 external-priority patent/WO2010075443A1/en
Publication of JP2012513411A publication Critical patent/JP2012513411A/ja
Publication of JP2012513411A5 publication Critical patent/JP2012513411A5/ja
Pending legal-status Critical Current

Links

JP2011542581A 2008-12-22 2009-12-22 Ａｋｔの選択的阻害剤およびその使用方法 Pending JP2012513411A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13975308P 2008-12-22 2008-12-22
US61/139,753 2008-12-22
PCT/US2009/069297 WO2010075443A1 (en) 2008-12-22 2009-12-22 Selective inhibitors of akt and methods of using same

Publications (2)

Publication Number Publication Date
JP2012513411A JP2012513411A (ja) 2012-06-14
JP2012513411A5 true JP2012513411A5 (https=) 2013-06-06

Family

ID=42288129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011542581A Pending JP2012513411A (ja) 2008-12-22 2009-12-22 Ａｋｔの選択的阻害剤およびその使用方法

Country Status (4)

Country Link
US (1) US20100168162A1 (https=)
EP (1) EP2381779A4 (https=)
JP (1) JP2012513411A (https=)
WO (1) WO2010075443A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103509009A (zh) * 2012-06-21 2014-01-15 中国科学院上海药物研究所 2-取代-5-苯基呋喃类化合物、其制备方法、药物组合物及其用途
US10577349B2 (en) 2015-03-02 2020-03-03 Sanford Burnham Prebys Medical Discovery Institute Quinolinones as inhibitors of translation initiation complex
CN119390701B (zh) * 2024-10-29 2025-11-25 中国药科大学 一种靶向降解pi3k蛋白的化合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098425A1 (en) * 2001-06-04 2002-12-12 Cytovia, Inc. Substituted 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20040171062A1 (en) * 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
AU2004233828B2 (en) * 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CN102225926A (zh) * 2003-11-07 2011-10-26 诺华疫苗和诊断公司 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
WO2005113762A1 (en) * 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
CA2600745A1 (en) * 2005-03-03 2006-09-08 The Burnham Institute For Medical Research Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby

Similar Documents

Publication Publication Date Title
JP2009298801A5 (https=)
Bigaud et al. Second generation S1P pathway modulators: research strategies and clinical developments
JP2019519519A5 (https=)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
FI3721882T3 (fi) Aineenvaihduntahäiriöiden hoito hevoseläimissä
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
JP2016536286A5 (https=)
JP2013067643A5 (https=)
JP2016539921A5 (https=)
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
BR112012002246A2 (pt) composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente
EP2478901A3 (en) Neurogenic compounds
JP2014533272A5 (https=)
JP2019530706A5 (https=)
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
JP2016513124A5 (https=)
EP4302825A3 (en) Pharmaceutical compositions for treatment of inappetence
JP2012513411A5 (https=)
JP2015513396A5 (https=)
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
KR20120085353A (ko) 가금류, 가축의 조류독감 및 호흡기 질환 치료제 및 예방제
MX2013006353A (es) Metodos y composiciones utiles para promover el sueño en animales.
EP4548924A3 (en) Enhanced delivery of drugs and other compounds to the brain and other tissues
RU2013150192A (ru) Метапневмовирус птиц в онколизисе
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof